Patient Safety and Health Care Quality of U.S. Laboratory Developed Tests (LDTs) in the AI/ML era of Precision Medicine Provisionally Accepted

Emma Kurnat-Thoma^{1, 2, 3*}

• ¹Consultant, United States
• ²Precision Policy Solutions, LLC, United States
• ³Georgetown Institute for Women, Peace, Security, Walsh School of Foreign Service, Georgetown University, United States

This policy brief summarizes current U.S. regulatory considerations for ensuring patient safety and health care quality of genetic/genomic test information for precision medicine in the era of artificial intelligence/machine learning (AI/ML). The critical role of innovative and efficient laboratory developed tests (LDTs) in providing accurate diagnostic genetic/genomic information for U.S. patient and family-centered healthcare decision-making is significant. However, many LDTs are not fully vetted for sufficient analytic and clinical validity via current FDA and CMS CLIA regulatory oversight pathways. The U.S. Centers for Disease Control and Prevention's Policy Analytical Framework Tool was used to identify the issue, perform a high-level policy analysis, and develop overview recommendations for a bipartisan healthcare policy reform strategy acceptable to diverse precision and systems medicine stakeholders.